P05
It is the unknown that defines our existence. We are constantly searching, not just for answers to our questions, but for new questions. We are explorers.

Latest

05
Dec

Fund of the week: Oberland Capital

In my November 25 post, I discussed "Royalties as a Credit Derivative," exploring how creative financing can extend
17 min read
04
Dec
Company of the Week: Dayra Therapeutics

Company of the Week: Dayra Therapeutics

Dayra Therapeutics is a Toronto-based biotech company developing oral macrocyclic peptide drugs for immunological diseases. The company launched in November
8 min read
03
Dec
Insuring Pharmaceutical Royalty Risks: Reinsurance and Case Studies

Insuring Pharmaceutical Royalty Risks: Reinsurance and Case Studies

The pharmaceutical royalty market has grown at a 45% CAGR since 2018, reaching over $6 billion in annual transaction volume—
32 min read
02
Dec
The CFO's Complete Guide to Pharmaceutical Royalty Financing: From Preclinical to Commercial

The CFO's Complete Guide to Pharmaceutical Royalty Financing: From Preclinical to Commercial

A stage-by-stage decision framework for evaluating synthetic royalties, royalty monetization, and alternatives in the $29 billion royalty financing market Pharmaceutical
12 min read
01
Dec
The Annuity Trap: Valuing Gene Therapy Royalties When Cash Flows Are Conditional

The Annuity Trap: Valuing Gene Therapy Royalties When Cash Flows Are Conditional

How outcome-based payment models are forcing royalty investors to rethink fundamental valuation assumptions—and what the early data reveals High-cost
18 min read
30
Nov
The Weekly Term Sheet (48)

The Weekly Term Sheet (48)

Biotech Transactions: November 23-29, 2025 GE HealthCare's $2.3 billion acquisition of Intelerad dominated a shortened Thanksgiving week
9 min read
29
Nov
China's clinical trial paradox: massive volume growth masks declining quality and FDA skepticism

China's clinical trial paradox: massive volume growth masks declining quality and FDA skepticism

Despite a 73% collapse in venture funding from $15.7B (2021) to $4.2B (2024), China's clinical trial
30 min read
28
Nov
Fund of the week: RA Capital Management

Fund of the week: RA Capital Management

RA Capital Management, the $12.6 billion biotech-focused investment firm founded in 2001, has aggressively expanded beyond its equity roots
18 min read
27
Nov
Company of the week: Hanmi Pharm (South Korea)

Company of the week: Hanmi Pharm (South Korea)

Company Overview Hanmi Pharm Co. is one of South Korea's leading pharmaceutical companies, distinguished by its heavy investment
11 min read
26
Nov
Japan's Biotech and Pharma Industry in 2025: Market Overview and Key Players

Japan's Biotech and Pharma Industry in 2025: Market Overview and Key Players

Introduction: A New Era for Japanese Pharmaceutical Innovation Japan's pharmaceutical landscape is undergoing a profound transformation. No longer
38 min read